Literature DB >> 19089638

The influences of cytokines as a possible substrate for the psychological effects of immunomodulation therapy in multiple sclerosis.

N N Spirin1, D S Kasatkin.   

Abstract

Changes in the emotional background make significant contributions to the clinical picture of multiple sclerosis (MS), seriously reducing patients' quality of life and hindering adaptation during the process of rehabilitation. The relationship between mental state and disease activity has been discussed in the world literature in recent years and the opinion that mental disorders in MS are pathogenetically based is increasingly widespread. The present article discusses the potential role of substances mediating immune responses-cytokines-in the effects of changes in the functional activity of the nervous system and psychoemotional status. The question of their likely involvement in the pathogenesis of the side effects of immunomodulatory therapy of MS with beta-interferons and glatiramer acetate is discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19089638     DOI: 10.1007/s11055-008-9087-1

Source DB:  PubMed          Journal:  Neurosci Behav Physiol        ISSN: 0097-0549


  82 in total

Review 1.  Cytokines and cognition--the case for a head-to-toe inflammatory paradigm.

Authors:  Craig J Wilson; Caleb E Finch; Harvey J Cohen
Journal:  J Am Geriatr Soc       Date:  2002-12       Impact factor: 5.562

Review 2.  Mechanisms of action of interferon-beta in multiple sclerosis.

Authors:  B G Arnason; A Dayal; Z X Qu; M A Jensen; K Genç; A T Reder
Journal:  Springer Semin Immunopathol       Date:  1996

3.  Influence of acute and repeated interleukin-2 administration on spatial learning, locomotor activity, exploratory behaviors, and anxiety.

Authors:  S Lacosta; Z Merali; H Anisman
Journal:  Behav Neurosci       Date:  1999-10       Impact factor: 1.912

Review 4.  Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress.

Authors:  A J Dunn; J Wang; T Ando
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

5.  Symptomatic fatigue in multiple sclerosis.

Authors:  J E Freal; G H Kraft; J K Coryell
Journal:  Arch Phys Med Rehabil       Date:  1984-03       Impact factor: 3.966

6.  Psychiatric complications of long-term interferon alfa therapy.

Authors:  P F Renault; J H Hoofnagle; Y Park; K D Mullen; M Peters; D B Jones; V Rustgi; E A Jones
Journal:  Arch Intern Med       Date:  1987-09

7.  Amelioration of flulike symptoms at the onset of interferon beta-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction.

Authors:  E M Martínez-Cáceres; J Río; M Barrau; I Durán; C Borrás; M Tintoré; X Montalban
Journal:  Ann Neurol       Date:  1998-10       Impact factor: 10.422

8.  Circadian rhythm of serum interleukin-6 in rheumatoid arthritis.

Authors:  N G Arvidson; B Gudbjörnsson; L Elfman; A C Rydén; T H Tötterman; R Hällgren
Journal:  Ann Rheum Dis       Date:  1994-08       Impact factor: 19.103

9.  Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism.

Authors:  J Wang; A J Dunn
Journal:  Neurochem Int       Date:  1998-08       Impact factor: 3.921

10.  Cytokine appearance in human endotoxemia and primate bacteremia.

Authors:  D G Hesse; K J Tracey; Y Fong; K R Manogue; M A Palladino; A Cerami; G T Shires; S F Lowry
Journal:  Surg Gynecol Obstet       Date:  1988-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.